ICON PLC (ICLR)

Currency in USD
205.14
-6.22(-2.94%)
Closed·
205.140.00(0.00%)
·
ICLR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
202.84211.00
52 wk Range
66.57219.04
Key Statistics
Prev. Close
211.36
Open
206
Day's Range
202.84-211
52 wk Range
66.57-219.04
Volume
766.09K
Average Volume (3m)
915.41K
1-Year Change
19.3924%
Book Value / Share
118.30
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ICLR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
231.29
Upside
+12.75%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

ICON PLC News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral

Analyst Ratings

10 Buy
7 Hold
1 Sell
Ratings:
18 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 231.29
(+12.75% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Mizuho
Buy228.00+11.14%190.00MaintainNov 02, 2026
Mizuho
Buy228.00+11.14%190.00MaintainOct 30, 2026
TD Cowen
Buy254.00+23.82%197.00MaintainOct 29, 2026
BMO Capital
Buy235.00+14.56%215.00MaintainOct 29, 2026
RBC Capital
Buy226.00+10.17%185.00MaintainOct 29, 2026

ICON PLC SWOT Analysis


CRO Market Dynamics
Explore ICON's navigation of industry challenges, including bookings volatility and demand uncertainties in the competitive CRO landscape
Financial Resilience
Delve into ICON's solid financial health, with EPS forecasts of $13.40 (FY1) and $14.06 (FY2), despite recent market pressures
Strategic Positioning
Learn how ICON leverages proprietary technology and global scale to capture high-quality opportunities in a shifting pharmaceutical landscape
Valuation Insights
Analysts set price targets ranging from $155 to $263, suggesting potential for value realization as transient headwinds subside
Read full SWOT analysis

ICON PLC Earnings Call Summary for Q3/2026

  • ICON posted Q3 2026 adjusted EPS of $2.66 on revenue of $2.02B, narrowly beating estimates; shares surged 6.62% premarket to $195.10.
  • Adjusted EBITDA margin expanded 70 bps sequentially to 16.6%; gross margin rose 90 bps to 24.7% driven by improved business mix and cost controls.
  • Record net business wins of $3.15B with 1.56x book-to-bill ratio marked fourth consecutive quarter above 1.3x, signaling strong demand momentum.
  • Management projects mid-single-digit revenue growth and higher single-digit earnings growth for 2027, though formal guidance deferred to Q4 results.
  • Revenue fell 2.9% YoY to $2.008B due to Symphony divestiture; free cash flow reached $302M with net debt at 2.0x leverage ratio.
Last Updated: 28/10/2026, 14:18
Read Full Transcript

Earnings

Latest Release
Oct 27, 2026
EPS / Forecast
2.66 / 2.64
Revenue / Forecast
2.02B / 2.01B
EPS Revisions
Last 90 days

ICLR Income Statement

Compare ICLR to Peers and Sector

Metrics to compare
ICLR
Peers
Sector
Relationship
P/E Ratio
35.7x30.0x−0.3x
PEG Ratio
0.58−1.580.00
Price/Book
1.7x3.0x2.6x
Price / LTM Sales
1.9x2.6x2.8x
Upside (Analyst Target)
12.9%19.3%66.4%
Fair Value Upside
Unlock2.2%9.0%Unlock

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
41.89M54.30%8.85B
Other Institutional Investors
40.93M45.70%8.65B
Public Companies & Retail Investors
0.000.00%0.00
Total
82.82M100.00%17.5B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Artisan Partners Limited Partnership11.19%8,636,4061,825,391
Artisan Partners Funds, Inc. - Artisan International Value Fund8.74%6,744,9021,425,602

People Also Watch

862.25
GEV
+0.51%
54.86
EQT
-0.95%
436.85
ISRG
+1.12%
228.85
APP
+0.15%
338.74
WDC
-7.48%

FAQ

What Is the ICON PLC (ICLR) Stock Price Today?

The ICON PLC stock price today is 205.14 USD.

What Stock Exchange Does ICON PLC Trade On?

ICON PLC is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for ICON PLC?

The stock symbol for ICON PLC is "ICLR."

What Is the ICON PLC Market Cap?

As of today, ICON PLC market cap is 15.30B USD.

What Is ICON PLC's Earnings Per Share (TTM)?

The ICON PLC EPS (TTM) is 5.65.

When Is the Next ICON PLC Earnings Date?

ICON PLC will release its next earnings report on Feb 24, 2027.

From a Technical Analysis Perspective, Is ICLR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has ICON PLC Stock Split?

ICON PLC has split 2 times.

How Many Employees Does ICON PLC Have?

ICON PLC has 40250 employees.

What is the current trading status of ICON PLC (ICLR)?

As of Nov 02, 2026, ICON PLC (ICLR) is trading at a price of 205.14 USD, with a previous close of 211.36 USD. The stock has fluctuated within a day range of 202.84 USD to 211.00 USD, while its 52-week range spans from 66.57 USD to 219.04 USD.

What Is ICON PLC (ICLR) Price Target According to Analysts?

The average 12-month price target for ICON PLC is 231.29 USD, with a high estimate of 268 USD and a low estimate of 180 USD. 10 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +12.75% Upside potential.

What Is the ICLR Premarket Price?

ICLR's last pre-market stock price is 213.87 USD. The pre-market share volume is 530.00, and the stock has decreased by 2.51, or 1.19%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.